Spectrum Pharma's cancer drug meets main goal in trial
April 23 (Reuters) - Spectrum Pharmaceuticals said its experimental cancer drug was shown to be safe and effective in a mid-stage trial.
Spectrum's drug, Captisol-enabled melphalan, is an intravenous formulation of a common chemotherapy drug melphalan, and is being tested in multiple myeloma patients undergoing stem cell transplants.
The company said it expects to file for a regulatory approval in the third quarter.
(Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila)